Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb

 
• By Alaric DeArment
Novartis sold Xiidra and ophthalmology pipeline assets to Bausch + Lomb • Source: Shutterstock

More from Deals

More from Business